CLINICAL TRIALS PROFILE FOR VANCOMYCIN HYDROCHLORIDE

505(b)(2) Clinical Trials for vancomycin hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01162733 ↗	Loading Vancomycin Doses in the Emergency Department	Completed	Christiana Care Health Services	N/A	2010-07-01	In 2008, our ED administered an average of 245 doses of vancomycin per month. Currently there is no consistency in the ED practice in regards to vancomycin dosing. In 2009, the IDSA put forth new recommendations for vancomycin dosing in order to achieve therapeutic levels more rapidly. It has been hypothesized that if therapeutic levels are reached more rapidly then patients will in turn have better clinical outcomes and that the development of resistant organisms will be decreased. Methicillin resistant Staphylococcus aureus (MRSA) has emerged as one of the most deadly pathogens that are currently plaguing our patient population. Vancomycin is one of only a few antibiotics that are effective for treating MRSA. It is imperative that the ED physicians consistently and correctly dose vancomycin in order to give the patients the best chance to fight infection while helping to prevent further resistance in this already highly resistant organism. It is believed this study will reveal that the new dosing recommendations by the IDSA will lead to the achievement of therapeutic levels more rapidly. This information will in turn help to convince ED physicians that a change in current clinical practice is warranted and ultimately lead to better clinically outcomes for the patients.
New Dosage	NCT01734694 ↗	Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients	Terminated	Henry Ford Health System	Phase 4	2011-10-01	For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.
OTC	NCT04674839 ↗	The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals	Completed	Microbio Co Ltd	N/A	2019-10-18	MicrSoy-20 (MS-20), a fermented soymilk product, has been approved as an Over the counter (OTC) drug in 2011. The therapeutic effect of MS-20 is to ameliorate symptoms such as fatigue and loss of appetite caused by cancer chemotherapy. Animal study revealed orally administration of MS-20 daily for 4 weeks altered the gut microbiota composition in mice. In addition, MS-20 could activate dendritic cell and improve immunotherapy response rate. Thus, it was hypothesis that MS-20 improves host immune activity thus ameliorate fatigue and increase weight is through alteration the gut microbiota composition. In this study, the ability of MS-20 in modulating gut microbiota and the subset of microbiome to be altered by MS-20 was investigated.

All Clinical Trials for vancomycin hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003805 ↗	Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1997-11-01	RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
NCT00034294 ↗	A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea	Completed	Genzyme, a Sanofi Company	Phase 2	2002-02-01	Approximately 300 patients will be entered into this study taking place throughout the United States, Canada and the United Kingdom. This study aims to determine if an investigational drug is safe and effective for treating the symptoms of C. difficile-associated diarrhea and lowering the risk of repeat episodes of diarrhea. The investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. All study-related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is approximately 10 weeks.
NCT00035425 ↗	Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection	Completed	Pfizer	Phase 3	2001-11-01	This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
NCT00035854 ↗	New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)	Completed	Pfizer	Phase 3	2002-02-01	This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
NCT00037050 ↗	Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria	Completed	Pfizer	Phase 3	2002-04-01	This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)
NCT00057369 ↗	Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections	Unknown status	Vicuron Pharmaceuticals	Phase 2	2001-02-01	This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin.

Clinical Trial Conditions for vancomycin hydrochloride

Condition Name

Condition Name for vancomycin hydrochloride
Intervention	Trials
Clostridium Difficile Infection	39
Surgical Site Infection	21
Infection	19
Clostridioides Difficile Infection	14

Condition MeSH

Condition MeSH for vancomycin hydrochloride
Intervention	Trials
Infections	163
Infection	141
Communicable Diseases	128
Clostridium Infections	85

Clinical Trial Locations for vancomycin hydrochloride

Trials by Country

Trials by Country for vancomycin hydrochloride
Location	Trials
Canada	102
Spain	43
United Kingdom	36
Australia	34
Brazil	34

Trials by US State

Trials by US State for vancomycin hydrochloride
Location	Trials
California	65
Texas	65
Ohio	53
Florida	51
New York	49

Clinical Trial Progress for vancomycin hydrochloride

Clinical Trial Phase

Clinical Trial Phase for vancomycin hydrochloride
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	4
PHASE2	16

Clinical Trial Status

Clinical Trial Status for vancomycin hydrochloride
Clinical Trial Phase	Trials
Completed	194
Recruiting	94
Terminated	48

Clinical Trial Sponsors for vancomycin hydrochloride

Sponsor Name

Sponsor Name for vancomycin hydrochloride
Sponsor	Trials
Cubist Pharmaceuticals LLC	23
Pfizer	18
Forest Laboratories	11

Sponsor Type

Sponsor Type for vancomycin hydrochloride
Sponsor	Trials
Other	601
Industry	179
U.S. Fed	17

Vancomycin Hydrochloride: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Vancomycin hydrochloride is a glycopeptide antibiotic primarily used to treat serious bacterial infections caused by Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). The drug's established efficacy and the persistent threat of antibiotic resistance underpin its continued market relevance. This analysis reviews recent clinical trial activity, assesses current market conditions, and projects future trends for vancomycin hydrochloride.

What is the current clinical trial landscape for vancomycin hydrochloride?

The clinical trial landscape for vancomycin hydrochloride is characterized by research focused on optimizing its delivery, managing resistance, and exploring novel applications. Trials are investigating improved formulations, alternative administration routes, and combination therapies.

Recent and Ongoing Clinical Trials:

• Formulation and Delivery Enhancements:

  • Oral Vancomycin for C. difficile Infection: While oral vancomycin has been a standard treatment for Clostridioides difficile infection (CDI) for some time, ongoing research explores dose optimization and extended-release formulations to improve patient compliance and efficacy. A Phase 3 trial (NCT05019836) is evaluating a novel oral formulation for recurrent CDI, aiming to reduce relapse rates.
  • Intravenous (IV) Vancomycin Optimization: Trials are assessing the impact of pharmacokinetic/pharmacodynamic (PK/PD) guided dosing on patient outcomes and reducing nephrotoxicity, a significant adverse effect. A study at the University of Michigan (NCT03657102) is examining the effect of therapeutic drug monitoring on vancomycin-associated kidney injury.

• Combination Therapies:

  • Vancomycin in Combination with Beta-Lactams: Research continues to investigate the synergistic potential of vancomycin with beta-lactam antibiotics for treating severe infections like endocarditis and osteomyelitis caused by increasingly resistant bacteria. A randomized controlled trial (RCT) in China (NCT04715464) is comparing vancomycin monotherapy to vancomycin plus ceftriaxone for hospital-acquired pneumonia.
  • Vancomycin with Novel Agents: Emerging trials explore combining vancomycin with new investigational antibiotics or adjunctive therapies to overcome resistance mechanisms and enhance killing power against difficult-to-treat pathogens. A Phase 2 study (NCT04781784) is testing vancomycin in combination with a novel investigational drug for MRSA bloodstream infections.

• Management of Vancomycin Resistance:

  • While vancomycin itself is not directly tested against resistant strains (as it is the treatment being bypassed), trials indirectly address resistance by seeking to preserve its utility. This includes studies on stewardship programs and the development of diagnostics to rapidly identify vancomycin-susceptible strains.

• Exploratory Applications:

  • Topical Vancomycin: Research is ongoing into the use of topical vancomycin in wound care and for the management of prosthetic joint infections to achieve high local drug concentrations and minimize systemic exposure. A small pilot study is investigating topical vancomycin in diabetic foot ulcers with suspected MRSA colonization.

Key Trial Characteristics:

• Focus Areas: CDI, MRSA infections, antibiotic stewardship, PK/PD optimization.
• Phases: Primarily Phase 2 and Phase 3, with some early-phase exploratory studies.
• Geographic Distribution: Trials are conducted globally, with significant activity in North America, Europe, and Asia.
• Sponsors: A mix of academic institutions, government agencies (e.g., NIH), and pharmaceutical companies (though many trials focus on generic vancomycin or combination therapies rather than novel vancomycin derivatives).

What are the market dynamics for vancomycin hydrochloride?

The market for vancomycin hydrochloride is shaped by its status as a well-established, off-patent antibiotic, the persistent prevalence of bacterial infections it targets, and the growing concern over antimicrobial resistance (AMR).

Market Size and Growth:

• Current Market Size: The global vancomycin hydrochloride market was valued at approximately $600 million in 2023.
• Projected Growth: The market is projected to grow at a compound annual growth rate (CAGR) of 3.5% to 4.0% from 2024 to 2030, reaching an estimated $750 million to $800 million by 2030. This growth is driven by increasing incidence of Gram-positive infections, particularly MRSA, and the rising prevalence of CDI.

Key Market Drivers:

• Prevalence of Gram-Positive Infections: The continued incidence of serious Gram-positive bacterial infections, especially those caused by MRSA, remains a primary driver. These infections necessitate the use of effective antibiotics like vancomycin, particularly in hospital settings.
• Antimicrobial Resistance (AMR): As resistance to other antibiotics (e.g., beta-lactams, macrolides) increases, vancomycin remains a critical treatment option for many challenging infections, thereby sustaining its demand.
• Aging Population: The global aging population is more susceptible to infections, leading to higher healthcare utilization and increased demand for antibiotics, including vancomycin.
• Growth in Hospital-Acquired Infections (HAIs): HAIs, including MRSA bloodstream infections and CDI, are a significant concern, driving the need for potent antibiotics like vancomycin in inpatient settings.
• Geographic Expansion: Increasing healthcare access and expenditure in emerging economies are contributing to market growth.

Market Restraints:

• Generic Competition: Vancomycin hydrochloride is largely a generic drug, leading to intense price competition among manufacturers and limiting significant revenue growth from drug price increases.
• Emergence of Resistant Strains: While vancomycin is used to combat resistance to other drugs, the emergence of vancomycin-resistant enterococci (VRE) and vancomycin-intermediate Staphylococcus aureus (VISA) strains poses a long-term threat to its efficacy and market share for specific infections.
• Development of Alternative Therapies: The development of newer antibiotics with novel mechanisms of action, or non-antibiotic therapies for conditions like CDI, could eventually displace vancomycin in certain indications.
• Adverse Events: Nephrotoxicity and ototoxicity associated with vancomycin can limit its use in certain patient populations or necessitate intensive monitoring, which can add to healthcare costs.

Competitive Landscape:

The vancomycin hydrochloride market is highly fragmented and competitive, dominated by generic manufacturers. Key players include:

• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (now part of Viatris)
• Fresenius Kabi AG
• Hikma Pharmaceuticals PLC
• Baxter International Inc.
• Pfizer Inc. (historically, though focus has shifted)
• Various Chinese and Indian generic manufacturers

Competition is primarily based on price, product quality, supply chain reliability, and market access. Manufacturers focus on efficient production processes and broad distribution networks.

Recent Market Developments:

• Supply Chain Resilience: Post-pandemic, there has been a heightened focus on ensuring the resilience and security of the supply chains for essential medicines like vancomycin.
• Stewardship Programs: Increased emphasis on antibiotic stewardship programs aims to optimize vancomycin use, ensuring it is prescribed appropriately and reducing the development of resistance. This can impact overall volume but reinforces its role for appropriate indications.
• Formulation Innovations: While major breakthroughs are less common for off-patent drugs, minor innovations in formulations (e.g., for ease of administration, stability) can offer competitive advantages.

What are the future projections for vancomycin hydrochloride?

The future of vancomycin hydrochloride is characterized by sustained demand for its established applications, tempered by the persistent challenges of antimicrobial resistance and the ongoing development of alternative treatments. Its role as a critical agent in combating Gram-positive infections, particularly in hospital settings, is expected to endure.

Projected Market Trends:

• Continued Demand for MRSA and Complicated Infections: The persistent threat of MRSA and other difficult-to-treat Gram-positive infections will ensure a steady demand for vancomycin. Its efficacy against these pathogens, where many other antibiotics fail, solidifies its position.
• Importance in CDI Treatment: Vancomycin will likely remain a cornerstone therapy for C. difficile infections, especially for severe or recurrent cases, despite emerging alternatives.
• Focus on Pharmacoeconomics and Stewardship: As healthcare systems grapple with rising costs and the imperative of AMR containment, there will be increased scrutiny on the cost-effectiveness and appropriate use of vancomycin. Antibiotic stewardship programs will continue to play a crucial role in guiding its prescription.
• Limited Innovation in Novel Vancomycin Compounds: Significant investment in developing new vancomycin derivatives is unlikely, given the drug's off-patent status and the focus on novel antibiotic classes with new mechanisms of action. Research will primarily focus on optimizing existing formulations and understanding its role in combination therapies.
• Regional Market Dynamics: Growth will be more pronounced in emerging markets where healthcare infrastructure is developing and infectious disease burden remains high. Developed markets will see more stable, albeit slower, growth driven by aging populations and HAI prevalence.
• Impact of Resistance Evolution: The gradual emergence and spread of VRE and VISA may lead to a decline in vancomycin's utility for specific patient populations or geographic regions, but it is unlikely to render the drug obsolete globally in the near to medium term. The development of resistance is typically slow and context-dependent.
• Competition from New Antibiotic Classes: The introduction of new antibiotics targeting Gram-positive pathogens or CDI could gradually erode vancomycin's market share in specific niches over the longer term (e.g., beyond 2030). However, the high cost and complex regulatory pathways for new antibiotics mean that vancomycin, with its established safety profile and low cost, will remain a primary option for many years.

Key Projections:

• Market Value: Projected to reach approximately $750 million to $800 million by 2030.
• CAGR: 3.5% to 4.0% for the forecast period (2024-2030).
• Therapeutic Areas: Dominant in hospital settings for MRSA infections, severe bacterial pneumonia, meningitis, endocarditis, and C. difficile infections.
• Geographic Focus: Continued strong presence in North America and Europe, with significant growth potential in Asia-Pacific and Latin America.
• Competitive Environment: Remains highly competitive with a focus on price and supply chain efficiency.

Strategic Considerations for Stakeholders:

• Manufacturers: Focus on maintaining high-quality, cost-effective production and robust supply chain management. Exploring niche formulations or delivery systems could offer marginal differentiation.
• Healthcare Providers: Emphasize strict antibiotic stewardship to optimize vancomycin use and preserve its efficacy. Invest in diagnostics to guide therapy.
• Researchers: Continue investigating the optimal use of vancomycin in combination therapies and exploring its role in combating emerging resistance patterns.
• Investors: Recognize the stable, albeit moderately growing, nature of the vancomycin market driven by persistent infectious disease challenges. Competition is primarily price-based, offering limited scope for significant margin expansion.

Key Takeaways

• Vancomycin hydrochloride remains a critical antibiotic for treating serious Gram-positive infections, particularly MRSA and C. difficile.
• Clinical trials are focused on optimizing delivery, managing resistance, and exploring combination therapies rather than developing novel vancomycin compounds.
• The global market is projected to reach $750-$800 million by 2030, with a CAGR of 3.5%-4.0%, driven by infection prevalence and AMR.
• The market is highly competitive and genericized, with pricing and supply chain reliability being key factors.
• Future demand is underpinned by its established efficacy and role in combating resistance, though evolving resistant strains and new antibiotic classes present long-term challenges.

FAQs

1. What is the primary indication for vancomycin hydrochloride? Vancomycin hydrochloride is primarily used to treat serious infections caused by Gram-positive bacteria, including Staphylococcus aureus (including MRSA), Streptococcus species, and Enterococcus species. It is also a key treatment for Clostridioides difficile infection.

2. What are the main side effects associated with vancomycin hydrochloride? The most significant potential side effects include nephrotoxicity (kidney damage) and ototoxicity (hearing damage). Red man syndrome, characterized by flushing and itching, can occur with rapid intravenous infusion.

3. How does antimicrobial resistance affect the use of vancomycin hydrochloride? While vancomycin is used to combat resistance to other antibiotics, the emergence of vancomycin-resistant strains (e.g., VRE, VISA) limits its effectiveness in specific situations and necessitates careful monitoring of susceptibility patterns.

4. What is the current market share of generic vancomycin hydrochloride compared to branded versions? Vancomycin hydrochloride is largely a generic drug. Branded versions have a minimal market share, with competition primarily among numerous generic manufacturers globally.

5. Are there any new formulations or delivery methods for vancomycin hydrochloride in development? Research is exploring enhanced formulations for oral vancomycin (e.g., for recurrent CDI) and optimizing intravenous dosing strategies based on PK/PD principles to minimize toxicity. Topical applications for wound care are also under investigation.

Citations

[1] ClinicalTrials.gov. (n.d.). Search of vancomycin. U.S. National Library of Medicine. Retrieved from https://clinicaltrials.gov/ [2] Global Market Insights, Inc. (2023). Vancomycin Hydrochloride Market Size, Share & Trends Analysis Report. [3] Mordor Intelligence. (2023). Vancomycin Hydrochloride Market - Growth, Trends, COVID-19 Impact, and Forecasts (2024-2029). [4] Fierce Pharma. (Various Dates). Company News & Drug Development Reports. Retrieved from https://www.fiercepharma.com/